Based on these studies, we have concluded that they have great potential for suppressing cytotoxic T lymphocyte (CTL) -mediated xenocytotoxicity and NK-mediated xenocytotoxicity. Furthermore, they also suppress macrophage-mediated xenocytotoxicity significantly. Here, we review the therapeutic potential of MDSCs in transplantation.
Introduction
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous cell populationof granulocytic and myeloid origin [1] . MDSCs were initially recognized in mice with tumor setting as a CD11b + Gr-1 + subset [2, 3] . Because of the absence of a Gr-1 gene homolog, human MDSCs had not been recognized until Zea et al. reported CD11b + CD14
-CD15 + granulocytic MDSCs in peripheral blood mononuclear cells (PBMCs) obtained from renal cancer patients [4] . CD14 + CD11b + HLA-DR low/neg monocytic MDSCs were subsequently identified in melanoma patients [5] . In addition to the tumor environment, the expansion of MDSC is widely recognized in various animal allogeneic graft models [6, 7, 8] . Garcia et al., based on depletion studies, reported that CD11b + G-1 + CD115 + monocytic MDSCs are
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responsible for the induction of tolerance in solid organ transplantation in an animal model [9] . However, the functions of human MDSCs in transplantation are not well recognized. Human CD14 + HLA-DR low/-MDSCs have been reported to favor the development of FoxP3 + Treg through the production of TGF-β [10] . Furthermore, Luan Y et al. reported that CD11b + CD33 + HLA-DR -MDSCs induce the production of regulatory T cells (Treg) in vitro and their accumulation after transplantation was correlated with an increase in Treg in vivo [11] . While in mouse transplantation models, bone marrow cells, of which 20-30% of are CD11b + Gr-1 + cells, can be used for a source of MDSCs, in humans, the preparation of MDSCs from bone marrow cells is not practical for clinical use. Recently we established a novel strategy for inducing human monocytic MDSCs from peripheral blood mononuclear cells (PBMCs) [12] . They have great potential for inhibiting xenogeneic cytotoxicity by cytotoxic T Lymphocytes [12] and NK cells [13] . Here, we review current strategies for the in vitro and in vivo generation of MDSCs and their therapeutic potential in xenotransplantation.
Strategies for the in vitro generation of human MDSCs from PBMCs
Lechner et al. initially reported on the vitro generation of human MDSCs from PBMCs obtained from healthy volunteers [14] . PBMCs were cultured for 7days with GM-CSF and various cytokines, such as IL-6, IL-1β, VEGF, etc. The cells were then harvested and CD33 positive cells were isolated by magnetic bead sorting and their suppressive ability against T cell proliferation by anti-CD3/CD28 beads and IFN-γ production by T cells were evaluated. The results from these studies demonstrated that CD33 + MDSCs generated with GM-CSF + IL-6 induced the most significant suppression. This was confirmed by a study of mouse MDSCs by Marigo et al., where the findings demonstrated that bone marrow derived MDSCs induced by GM-CSF + IL-6 exhibited the highest tolerogenic activity [15] . In addition, they concluded that MDSCs induced by GM-CSF + IL-6 lead to increases of CD25 + FoxP3 + Treg, resulting in the suppression of T cell proliferation. Furthermore, in another article, a different strategy for generating MDSCs from normal donor PBMCs was reported [16] . Donor PBMCs were co-cultured with various human solid tumor cell lines for 1week. MDSCs were then isolated by magnetic column separation using anti-CD33 or anti-CD11b microbeads. Tumor-derived GM-CSF, IL-6, TNF-α, and VEGF were found to induce MDSC differentiation. Both CD11b + and CD33 + tumor-induced MDSCs also suppressed T cell proliferation. More recently, we established a method for isolating human MDSCs in an extremely shorter period from peripheral blood compared to other methods (Figure1A). To generate MDSCs from PBMCs, peripheral blood monocytes Figure 1A . Strategy for the generation of human monocytic MDSCs from peripheral blood. Peripheral blood-derived monocytes were cultured with 100ng/ml of GM-CSF and 100ng/ml of IL-4 for 24hours and activated by treatment with 100ng/ml of LPS or 25μg/ml of poly-IC for 24hours. The cells were harvested by gentle pipetting and HLA-DR positive cells were depleted using magnetic bead separation. The HLA-DR negative fraction was used as MDSCs. Reprint with permission [12] .
were cultured with GM-CSF and IL-4 for 24hours and subsequently activated with LPS or poly I:C for 24hours. LPS and poly I:C-induced activation resulted in a significant increase in the percentage of CD14 + cells and CD33 + cells in HLA-DR -cells (Fig 1B) . To isolate monocytic MDSCs HLA-DR -cells, they were depleted by magnetic bead sorting and more than 95% of the isolated cells were found to be CD14 + HLA-DR -.
One of the problems associated with the preparation of MDSCs from PBMCs for clinical use is the difficulty in improving the yield of MDSCs. MDSCs can be prepared from marrow from animals. Because bone marrow cells contain high levels of hematopoietic stem cells, sufficient amounts of murine MDSCs are generated from murine bone marrow cells co-cultured with a low dose of GM-CSF [17] . On the other hand, PBMCs from healthy donors include only a few myeloid progenitor cells. Therefore, it is difficult to obtain sufficient amounts of MDSCs from peripheral blood for clinical use. As shown in Fig1B, more than 50% of peripheral blood monocytes differentiate into CD14 + HLA-DR -MDSCs, suggesting that not only myeloid progenitor cells but also monocytes can differentiate into monocytic MDSCs. For the clinical use of MDSCs from PBMCs, more advanced strategies for producing MDSCs from peripheral blood monocytes but not progenitor cells are mandatory.
Monocytic MDSCs from peripheral blood suppress both NK and CTL mediated cytotoxicity in xenogeneic setting
Although xenotransplantation is one of the most attractive strategies for overcoming the worldwide shortage of organs, immune rejection is a major hurdle in successful xenograft transplantations. There are multiple immunologic barriers to the successful transplantation of xenografts. The first is hyperacute rejection (HAR), which is mediated by xenoreactive natural antibodies and/or complement [18] . These natural antibodies are directed against the α-galactosyl xenoantigen (α-Gal) carbohydrate epitopes that are present on the human vascular endothelium [19, 20] . The second barrier to xenotransplantion is delayed xenograft rejection (DXR) which occurs between several days to weeks after transplantation and is also mediated by natural antibodies [21] . Both HAR and DXR are primarily relevant to whole organ grafts rather than cellular grafts. Both types of rejection may be prevented by the depletion of natural antibodies and complement. After overcoming HAR and DXR, the xenograft might become susceptible to cellular rejection, which is mediated by monocytes, macrophages, NK cells and T cells. It is well known that human NK cells induce extensive cell lysis of porcine endothelial cells (PEC) and play an important role in xenogeneic rejection [22] [23] [24] . Therefore, we studied the suppressive function of human MDSCs against NK-mediated xenogeneic cell lysis [13] . Peripheral blood-derived MDSCs significantly suppressed human NK cell-mediated xenocytotoxicity. Previously, human CD8+ cytotoxic T lymphocytes (CTLs) were demonstrated to induce the xenogeneic rejection of pig cells [25] . Hence, we checked the suppressive ability against xenogeneic CTL-induced cytotoxicity. The cytotoxicity mediated by 1×10
6 CTLs was significantly suppressed by 3 x 10 4 peripheral blood-derived MDSCs, suggesting that monocytic MDSCs derived from peripheral blood monocytes can be extremely effective against xenogeneic rejection [12] . Furthermore, monocytic MDSCs express significant amounts of indoleamine 2,3-dioxygenase (IDO) and suppress CTL-induced cytotoxicity in an IDO-dependent manner. A mixed lymphocyte reaction (MLR) revealed that blood-derived MDSCs also suppress the proliferation of Figure 1B . Strategy for the generation of human monocytic MDSCs from peripheral blood. Peripheral blood monocytes were cultured for 24 hours with GM-CSF and IL-4, followed by activation with LPS or poly I:C. At 24hours after activation, the cells were harvested by gentle pipetting and stained with APC conjugated anti-CD14 and PE conjugated anti-HLA-DR (Before sorting). The expression of CD14 and HLA-DR in the HLA-DR negative fraction (MDSCs) was checked by flow cytometry. More than 95% of MDSCs was CD14 + HLA-DR -(After Sorting). Reprint with permission [12] .
xenogeneic T cells. These findings indicate that blood-derived monocytic MDSCs are effective in both CTL generation and CTL-mediated cytotoxicity.
Monocytic MDSCs suppress macrophage-mediated cytotoxicity
Macrophages have been found to be involved in CXR [26] . Macrophages are activated by pathogen-associated molecular patterns (PAMPS) and NOD like receptor (NLR) ligands. Currently available evidence supports the notion that a macrophage-mediated rejection of xenografts occurs beyond HAR and DXR. Primate macrophages have been shown to mediate the xenograft rejection of porcine hematopoietic cells and pancreatic islets that are depleted of the α-Gal antigen, which is thought to trigger HAR and DXR [27] [28] [29] [30] . In addition, human macrophages have been demonstrated to phagocytose porcine red blood cells in the absence of an antibody or complement opsonization [31] . It has also been reported that the removal of α-Gal epitopes from porcine cells fails to prevent this phagocytosis. Genetically engineered knockout pigs that no longer express α-Gal epitopes have been developed [32] [33] [34] . Although the survival of hearts derived from these pigs in baboons is significantly prolonged, they are still eventually rejected compared to normal pigs [35] . Macrophages are activated via 2 different processes in a xenogeneic setting. T cells activate macrophages, resulting in the infiltration of macrophages into the xenograft, thus leading to further T cell activation. Another is the direct graft destruction by macrophages independent of T cells. Macrophages have been shown to induce the rejection of transplanted xenogeneic bone marrow in the absence of adaptive immunity [27, 36] . We evaluated the suppressive activity of MDSCs obtained from peripheral blood on macrophage-mediated direct cytotoxicity in a xenogeneic setting [37] . Monocyte-derived MDSCs showed a significant suppression in macrophage-mediated xenocytotoxicity in an IDO-dependent manner. In addition, MDSCs significantly suppressed the release of nitric oxide (NO) from macrophages and NO suppression was induced in an IDO and arginase-1 (Arg-1) dependent manner. MDSCs have been reported to induce the differentiation into M2 macrophages by some investigators [38, 39] . These findings are consistent with our findings and indicate that MDSCs may suppress antigen presentation to T cells as well as macrophage-mediated cytotoxicity.
Strategies for in vivo MDSC expansion in allotransplant models
An anti-CD28 antibody treatment was reported to induce the production of monocytic MDSCs, resulting in tolerance in a rat model of a kidney allograft. CD3 -MHCII -CD11b + CD80/86 + cells accumulated in the blood and grafts of tolerant recipients. These cells were identified as MDSCs that inhibited the proliferation of effector T cells. An increased expression of iNOS in blood-derived MDSCs has been demonstrated by quantitative PCR and the suppressive function was dependent on iNOS from blood-derived MDSCs. Furthermore, the injection of amino guanidine, an iNOS inhibitor, induced the rejection of allografts. These observations suggest that peripheral blood-derived MDSCs also suppress effector T cell expansion in a graft as well as graft-infiltrating MDSCs. [6] .
De Wilde et al. reported on the suppressive activity of lipopolysaccharide (LPS)-induced MDSCs in an allogeneic transplantation model [40] . Repeated injections of LPS induced an increased production of MDSCs. The expanded CD11b + Gr-1 + cells suppressed T-cell proliferation and Th1 and Th2 cytokine production in in vitro allogeneic responses. The transfer of MDSCs into naive recipients resulted in a prolonged skin allograft survival. This study identified heme oxygenase-1 (HO-1) as the main mechanism responsible for the MDSC induced suppression in alloreactive T cells. Another recent report demonstrated that repeated injections of LPS with IFN-γ resulted in the expansion of two distinct cell populations in the mouse spleen but not in lymph nodes [41] . Both Gr-1low CD11 bright Ly6C high SSC low monocytic MDSCs and Gr-1 high CD11b low granulocytic MDSCs inhibit DC generation and CD8 + T cell proliferation. These data indicate that the spleens of healthy mice contain at least two subsets of MDSC, and a combined LPS and IFN-γ treatment expanded and activated MDSCs. Ochando et al. reported on the role of monocytic MDSCs in long-term survival induced by a co-stimulatory blockade with an anti-CD40 ligand in a mouse heart transplantation model. In their study, CD11b + CD115 + Gr-1 + monocytic MDSCs suppressed the initiation of adaptive immune responses and participated in the development of Tregs [9] . IL-33 has recently been reported to prolong allograft survival in cardiac grafts by some groups [42] [43] [44] . IL-33 is known to be a nuclear cytokine and one of the IL-1 family of cytokines. In addition, IL-33 is released from necrotic cells as an alarmin and activates both innate and acquired immunity [45] [46] [47] [48] [49] [50] [51] . . Innate immune stimuli such as LPS and IL-33 act as a double edged sword. It depends on the timing of the stimulation, the concentration of stimulation and the combination of various stimuli whether these stimuli induce am inflammatory or an anti-inflammatory effect.
Subsets of monocytic MDSCs and mechanisms of suppressive function in transplantation
In mouse models, differences between granulocytic MDSCs and monocytic MDSCs in suppressive mechanisms have been reported. While granulocytic MDSCs express high levels of reactive oxigen species (ROS) and low levels of NO, monocytic MDSCs express high levels of NO and low levels of ROS. Furthermore, some reports suggest that there are 2 subclasses of mouse monocytic MDSCs, i.e., M1-like MDSCs and M2-like MDSCs [38, 52, 53] . The differences in function between M1-like and M2-like MDSCs were reported in these articles. While M1-like MDSCs express iNOS and release high levels of NO and low levels of ROS, M2-like MDSCs express high levels of Arg-1 and exhibit M2-like characteristics. Previous reports by Rutschman et al. [54] and Bronte V et al. [55] , using tumor-bearing mice demonstrated that the combination of GM-CSF and IL-4 induces the production of Arg-1 + M2-like MDSCs which have a suppressive ability in allogeneic T cell responses. Mandruzzato et al. [56] demonstrated a significant suppression in T cell proliferation by IL-4Rα + MDSCs. Furthermore, regarding transplantation Highfill et al. demonstrated that IL-13, in combination with G-CSF and GM-CSF, develop Arg-1 + MDSCs which inhibit the graft-versus-host disease (GVHD) [57] . These findings indicate that the activation of STAT6 signaling through the binding of IL-4 or IL-13 to IL-4Rα is important for the induction of M2-like MDSCs. In addition Ma et al. demonstrated that the genetic ablation of the paired immunoglobulin-like receptor B (PIR-B) induces M1-like MDSC differentiation, resulting in a decreased suppressive function and an increased tumor growth [53] . In a mouse skin graft model, it was reported that the interaction between immunoglobulin-like transcript 2 (ILT2) and HLA-G is involved in the expansion of MDSCs [58] .
Various mechanisms for MDSC-induced suppression of the T cell and NK cell response have been proposed. Although both G-MDSC and M-MDSC have been reported to suppress T cell responses, each of these are different. While G-MDSCs inhibit T cell responses through ROS [59, 60] , M-MDSCs suppress T cell responses via the depletion of L-arginine by upregulating arginase-1 and iNOS [61] [62] [63] [64] [65] . In mouse transplantation models, iNOS has been shown to be critical for MDSC-induced immunological tolerance by some groups [6, 9, 66] . Furthermore, the development of regulatory T cells (Treg) has been reported to be induced by MDSCs, resulting in the induction of transplantation tolerance. While some reports have shown that MDSCs develop Treg through IFN-γ and iNOS-dependent pathways, resulting in the prolongation of allograft survival [67] [68] [69] , other studies have reported that IL-10, IL-4R, and arginase have a positive effect, but not iNOS [62, 70] . Ochando et al. hypothesized that iNOS from MDSCs may indirectly promote Treg survival through inducing the death of effector T cells [71] .
In our strategy for generating MDSCs, a low dose of GM-CSF in combination with IL-4 appears to induce the expansion and differentiation of Arg-1 + M2-like MDSCs from monocytes. In addition, immune complexes have been reported to induce the production of M2b macrophages in combination with LPS [72] , while LPS is known to induce the production of M1-like MDSCs independently. Therefore, LPS may induce differentiation into not only M1-like MDSCs but also M2-like MDSCs. However, no subpopulations of human monocytic MDSCs have yet to be identified as of this writing. Because studies of human MDSCs are extremely limited, further investigations of human MDSCs will clearly be of help in developing more advanced strategies for generating MDSCs.
Conclusion
One of the major goals in both allo and xenotransplantation is the induction of tolerance to a grafted organ that becomes free from transplant rejection and treatment with immunosuppressive drugs and their side effects. One approach is the adoptive transfer of in vitro generated MDSCs to control immune responses or to induce tolerance. A recent study in this laboratory demonstrated that functional MDSCs can successfully be generated from human peripheral blood. The cells significantly inhibited T cell proliferation induced in a xenogeneic setting in vitro. Furthermore, peripheral blood-derived MDSCs were successful in suppressing NK and macrophage-mediated cytotoxicity, suggesting that peripheral blood-derived MDSCs have great clinical potential for use in xenotransplantation. Because cellular rejection is involved in both allo and xenograft rejection, our results suggest that blood -derived MDSCs might also be effective in allograft rejection.
Another approach is the in vivo generation of monocytic MDSCs. Various innate inflammatory stimulatory molecules, such as LPS and IL-33, are known to induce both innate inflammation and the expansion of MDSCs, indicating that various innate stimuli act as double-edged swords. While the administration of a high dose LPS induces septic shock, a low dose induces immunological tolerance [73] . Therefore, in these strategies using innate inflammatory stimuli, optimization of the applied dose may be the first consideration for clinical use. On the other hand, there are no worries regarding the administration of LPS or poly-IC-activated MDSCs concerning septic shock because inflammatory cells are depleted in vitro. If equipment for cell culture and sorting system are ready to use, this point will become an advantage for in vivo generation. However, the methods used to administer MDSCs should be discussed carefully before implementation. One such candidate is administration by pheresis. Among the various types of pheresis, extracorporeal photopheresis (ECP) is well known to have therapeutic potential in transplant rejections, especially in cases of cardiac transplant rejection [74] . ECP has been reported to affect peripheral blood monocytes, resulting in the induction of Treg and the development of immunological tolerance [75, 76] . The ECP procedure may be of help in clinical applications of human MDSCs. For the clinical use of in vitro generated MDSCs, they should migrate to the graft tissue. However, the available information concerning the migration of in vitro generated MDSCs is currently very limited. Hence, an in vivo migration assay using an animal model is worth considering. Another candidate is a practical application of MDSCs to cell transplantation. Because cellular rejection is relevant to both whole organ transplants and cellular grafts, MDSCs could be used in treating, not only organ transplants but also cellular grafts. In cellular grafts such as islet cells and haematopoietic stem cell transplantation, the co-injection of MDSCs may induce local tolerance without the development of general immunosuppression, indicating that patients might be free from various side effects induced by immunosuppressive drugs.
Anti-CD28 and antu-CD40L antibodies are expected to induce the suppression of innate immune reactions via the induction of MDSCs as well as the inhibition of acquired immunity via a co-stimulatory blockade. Hence, these strategies might be able to be applied to not only allogeneic rejections but also xenogeneic rejections.
In conclusion, MDSCs suppress a wide range of immune responses, indicating that they are widely applicable in transplantation. It is particularly noteworthy that monocytic MDSCs have been reported to suppress graft rejection by many investigators. For clinical use, either an in vitro preparation of MDSCs from peripheral blood or the in vivo generation of MDSCs are the most practical methods. However, to put them into clinical practice, further investigations are necessary because of our extremely poor current understanding of human MDSCs. More advanced identification of subsets of human MDSCs may be a novel strategy for transplantation using human MDSCs. In addition, the precise optimization of inflammatory stimuli such as GM-CSF and LPS is necessary because these stimuli induce completely opposite immunological functions, depending on their concentration and the combination with other stimuli.
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